Insmed to Present 11 Abstracts from Across Its Respiratory Portfolio at the American Thoracic Society 2025 International Conference

Core Insights - Insmed Incorporated will present 11 abstracts from its respiratory portfolio at the ATS 2025 International Conference, focusing on the efficacy and safety of brensocatib and health outcomes in patients with Mycobacterium Avium Complex lung disease [1][2][26] Group 1: Company Overview - Insmed is a global biopharmaceutical company dedicated to developing first- and best-in-class therapies for serious diseases [1][26] - The company is advancing a diverse portfolio of approved and investigational medicines, particularly in pulmonary and inflammatory conditions [26][27] Group 2: Research and Development - The Phase 3 ASPEN study is the largest clinical trial in bronchiectasis to date, evaluating brensocatib's performance across various patient subgroups [2][6] - New health economics and outcomes research related to MAC lung disease will also be presented, highlighting treatment patterns and health status improvements [1][3] Group 3: Upcoming Presentations - Presentations will include analyses of treatment patterns in non-cystic fibrosis bronchiectasis and healthcare resource utilization for MAC lung disease [3] - Specific sessions will focus on the efficacy of brensocatib in patients with different backgrounds, including those with eosinophilic bronchiectasis [3][9]